Preventing recurrence of Clostridium difficile infection (CDI)

24 April 2017
1128 Views

New data presented today at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, demonstrate benefits of extended-pulsed fidaxomicin (EPFX), compared to standard vancomycin.

Data from the EXTEND study show that EPFX provides a superior rate of sustained clinical cure at 30 days following treatment compared to standard vancomycin. At 40 days, recurrence rates were also found to be almost 10 times lower in patients treated with EPFX compared with standard vancomycin. EPFX is currently not an approved dosing regimen.

“The results of the study show at 30 days after end of treatment (i.e. day 55 for extended fidaxomicin (EPFX) and day 40 for vancomycin), recurrence occurred in 4.0% and 16.8% of patients receiving EPFX and vancomycin, respectively”, commented study author Professor Benoit Guery, Infectious Diseases Services, University Hospital of Lausanne. “The EXTEND study shows superiority of extended fidaxomicin over vancomycin1 and importantly this result is obtained with the same number of tablets and therefore does not change the cost and clearly improves the cost-efficacy ratio.” The extended-pulsed fidaxomicin regimen means that patients receive the same number of tablets as the standard licensed course of fidaxomicin (one tablet administered twice daily for 10 days), but over a longer period of time.

A randomised, controlled, open-label study, the EXTEND trial is the first multicentre study of clinical outcomes for EPFX and was conducted in hospitals in 22 European countries.

Dr. Andreas Karas, Senior Medical Director, Astellas Pharma EMEA, commented, “Recurrence of disease is one of the largest ongoing unmet needs of CDI treatment and the EXTEND study was designed to specifically get this as low as possible by minimising the impact on the gut flora by using a pulsed dosing regimen. Getting recurrence to levels as low as shown in this trial is a positive outcome for patients but also for health systems that bear the economic burden”.

Economic analyses of the EXTEND study data indicate that EPFX is a cost-effective treatment strategy compared with standard vancomycin.  This finding was driven by the reduction in hospitalisation costs, resulting from the reduced recurrence rates associated with EPFX.

Fidaxomicin is indicated in adults for the treatment of CDI. The recommended dose is one 200mg tablet administered twice daily for 10 days. Extended-pulsed regimen with fidaxomicin is not currently approved.

You may be interested

Turkey provokes Greece calling for dialogue over “Turkish” minority in Thrace
SLIDE
shares18 views
SLIDE
shares18 views

Turkey provokes Greece calling for dialogue over “Turkish” minority in Thrace

makis - Jul 08, 2020

In an interview with Turkish Anadolu News Agency, Ibrahim Kalin, the presidential spokesperson and special adviser to the President of…

Coronavirus: New air filter traps the virus & destroys it
GREECE
shares34 views
GREECE
shares34 views

Coronavirus: New air filter traps the virus & destroys it

Panos - Jul 08, 2020

Researchers in the United States have announced that they have developed an effective air filter that can immediately trap and…

Stop buying Turkey’s F-35 parts, lawmakers tell DoD
GREECE
shares27 views
GREECE
shares27 views

Stop buying Turkey’s F-35 parts, lawmakers tell DoD

Panos - Jul 08, 2020

A bipartisan group of lawmakers is urging the Pentagon to more quickly stop buying F-35 fighter jet components from Turkey.…

Leave a Comment

Your email address will not be published.